BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rossi G, Gramegna D, Paoloni F, Fattizzo B, Binda F, D’adda M, Farina M, Lucchini E, Mauro FR, Salvi F, Marchetti M, Fazi P, Zaja F, Barcellini W. Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study. Blood 2018;132:547-50. [DOI: 10.1182/blood-2018-03-835413] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Liu M, Jin M, Li L, Ji Y, Zhu F, Luo Y, Liu T, Lin B, Lu Y. PDMS Microwell Stencil Based Multiplexed Single‐Cell Secretion Analysis. Proteomics 2020;20:1900231. [DOI: 10.1002/pmic.201900231] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
2 Yao M, Zhang J, Li Y, Lv L, Jia L, Yang C, Huang Y, Liu H, Wang J, Chen M, Zhang H. Combination of low-dose rituximab, bortezomib and dexamethasone for the treatment of autoimmune hemolytic anemia. Medicine (Baltimore) 2022;101:e28679. [PMID: 35089216 DOI: 10.1097/MD.0000000000028679] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Gertz MA. Waldenström macroglobulinemia: 2019 update on diagnosis, risk stratification, and management. Am J Hematol 2019;94:266-76. [PMID: 30328142 DOI: 10.1002/ajh.25292] [Cited by in Crossref: 45] [Cited by in F6Publishing: 29] [Article Influence: 15.0] [Reference Citation Analysis]
4 Barcellini W, Giannotta JA, Fattizzo B. Autoimmune Complications in Hematologic Neoplasms. Cancers (Basel) 2021;13:1532. [PMID: 33810369 DOI: 10.3390/cancers13071532] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5 Barcellini W, Fattizzo B, Zaninoni A. Management of refractory autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation: current perspectives. J Blood Med 2019;10:265-78. [PMID: 31496855 DOI: 10.2147/JBM.S190327] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
6 Barcellini W, Fattizzo B, Zaninoni A. Current and emerging treatment options for autoimmune hemolytic anemia. Expert Rev Clin Immunol 2018;14:857-72. [PMID: 30204521 DOI: 10.1080/1744666X.2018.1521722] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
7 Jia MN, Qiu Y, Wu YY, Cai H, Zhou DB, Cao XX, Li J. Rituximab-containing therapy for cold agglutinin disease: a retrospective study of 16 patients. Sci Rep 2020;10:12694. [PMID: 32728060 DOI: 10.1038/s41598-020-69465-2] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Heath JR. Framing technology challenges associated with improving cancer immunotherapies. Lab Chip 2019;19:3366-7. [PMID: 31559406 DOI: 10.1039/c9lc90103e] [Reference Citation Analysis]
9 Liu AP, Cheuk DK. Disease-modifying treatments for primary autoimmune haemolytic anaemia. Cochrane Database Syst Rev 2021;3:CD012493. [PMID: 33786812 DOI: 10.1002/14651858.CD012493.pub2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Brown CE, Mackall CL. CAR T cell therapy: inroads to response and resistance. Nat Rev Immunol 2019;19:73-4. [DOI: 10.1038/s41577-018-0119-y] [Cited by in Crossref: 81] [Cited by in F6Publishing: 70] [Article Influence: 27.0] [Reference Citation Analysis]
11 Zaninoni A, Giannotta JA, Gallì A, Artuso R, Bianchi P, Malcovati L, Barcellini W, Fattizzo B. The Immunomodulatory Effect and Clinical Efficacy of Daratumumab in a Patient With Cold Agglutinin Disease. Front Immunol 2021;12:649441. [PMID: 33732266 DOI: 10.3389/fimmu.2021.649441] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
12 Sefland Ø, Randen U, Berentsen S. Development of Multiple Myeloma of the IgA Type in a Patient with Cold Agglutinin Disease: Transformation or Coincidence? Case Rep Hematol 2019;2019:1610632. [PMID: 30949369 DOI: 10.1155/2019/1610632] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
13 Berentsen S. How I treat cold agglutinin disease. Blood 2021;137:1295-303. [PMID: 33512410 DOI: 10.1182/blood.2019003809] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
14 Gertz MA. Waldenström macroglobulinemia: 2021 update on diagnosis, risk stratification, and management. Am J Hematol 2021;96:258-69. [PMID: 33368476 DOI: 10.1002/ajh.26082] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 15.0] [Reference Citation Analysis]
15 Jäger U, Barcellini W, Broome CM, Gertz MA, Hill A, Hill QA, Jilma B, Kuter DJ, Michel M, Montillo M, Röth A, Zeerleder SS, Berentsen S. Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting. Blood Rev 2020;41:100648. [PMID: 31839434 DOI: 10.1016/j.blre.2019.100648] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 18.3] [Reference Citation Analysis]
16 Gertz MA. Updates on the Diagnosis and Management of Cold Autoimmune Hemolytic Anemia. Hematology/Oncology Clinics of North America 2022. [DOI: 10.1016/j.hoc.2021.11.001] [Reference Citation Analysis]
17 Berentsen S, Barcellini W, D'Sa S, Randen U, Tvedt THA, Fattizzo B, Haukås E, Kell M, Brudevold R, Dahm AEA, Dalgaard J, Frøen H, Hallstensen RF, Jæger PH, Hjorth-Hansen H, Małecka A, Oksman M, Rolke J, Sekhar M, Sørbø JH, Tjønnfjord E, Tsykunova G, Tjønnfjord GE. Cold agglutinin disease revisited: a multinational, observational study of 232 patients. Blood 2020;136:480-8. [PMID: 32374875 DOI: 10.1182/blood.2020005674] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
18 Berentsen S, Röth A, Randen U, Jilma B, Tjønnfjord GE. Cold agglutinin disease: current challenges and future prospects. J Blood Med 2019;10:93-103. [PMID: 31114413 DOI: 10.2147/JBM.S177621] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 5.3] [Reference Citation Analysis]
19 Patriquin CJ, Pavenski K. O, wind, if winter comes … will symptoms be far behind?: Exploring the seasonality (or lack thereof) and management of cold agglutinin disease. Transfusion 2021. [PMID: 34893982 DOI: 10.1111/trf.16765] [Reference Citation Analysis]
20 Pessach I, Dimopoulos MA, Kastritis E. Managing complications secondary to Waldenström's macroglobulinemia. Expert Rev Hematol 2021;:1-12. [PMID: 34170207 DOI: 10.1080/17474086.2021.1947236] [Reference Citation Analysis]
21 Fadlallah J, Michel M, Crickx E, Limal N, Costedoat N, Malphettes M, Fieschi C, Galicier L, Oksenhendler E, Godeau B, Audia S, Mahévas M. Bortezomib and dexamethasone, an original approach for treating multi‐refractory warm autoimmune haemolytic anaemia. Br J Haematol 2019;187:124-8. [DOI: 10.1111/bjh.16009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
22 Wei W, Fan R. Special Issue on Single-Cell Multiomics for Immuno-Oncology and Cancer Systems Biology. Proteomics 2019;19:e1900235. [PMID: 31411816 DOI: 10.1002/pmic.201900235] [Reference Citation Analysis]
23 Pasquale R, Giannotta JA, Barcellini W, Fattizzo B. Bortezomib in autoimmune hemolytic anemia and beyond. Ther Adv Hematol 2021;12:20406207211046428. [PMID: 34795889 DOI: 10.1177/20406207211046428] [Reference Citation Analysis]
24 Wang X, Scarfò I, Schmidts A, Toner M, Maus MV, Irimia D. Dynamic Profiling of Antitumor Activity of CAR T Cells Using Micropatterned Tumor Arrays. Adv Sci (Weinh) 2019;6:1901829. [PMID: 31832320 DOI: 10.1002/advs.201901829] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
25 Berentsen S, Hill A, Hill QA, Tvedt THA, Michel M. Novel insights into the treatment of complement-mediated hemolytic anemias. Ther Adv Hematol 2019;10:2040620719873321. [PMID: 31523413 DOI: 10.1177/2040620719873321] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
26 Bowman N, Liu D, Paczkowski P, Chen J, Rossi J, Mackay S, Bot A, Zhou J. Advanced Cell Mapping Visualizations for Single Cell Functional Proteomics Enabling Patient Stratification. Proteomics 2020;20:e1900270. [PMID: 32108428 DOI: 10.1002/pmic.201900270] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
27 Gabelli M, Ademokun C, Cooper N, Amrolia PI. Pathogenesis, risk factors and therapeutic options for autoimmune haemolytic anaemia in the post-transplant setting. Br J Haematol 2021. [PMID: 34195990 DOI: 10.1111/bjh.17648] [Reference Citation Analysis]
28 Barcellini W, Zaninoni A, Giannotta JA, Fattizzo B. New Insights in Autoimmune Hemolytic Anemia: From Pathogenesis to Therapy Stage 1. J Clin Med 2020;9:E3859. [PMID: 33261023 DOI: 10.3390/jcm9123859] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
29 Giannotta JA, Fattizzo B, Cavallaro F, Barcellini W. Infectious Complications in Autoimmune Hemolytic Anemia. J Clin Med 2021;10:E164. [PMID: 33466516 DOI: 10.3390/jcm10010164] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
30 Xiao Z, Murakhovskaya I. Development of New Drugs for Autoimmune Hemolytic Anemia. Pharmaceutics 2022;14:1035. [DOI: 10.3390/pharmaceutics14051035] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Hill A, Hill QA. Autoimmune hemolytic anemia. Hematology Am Soc Hematol Educ Program 2018;2018:382-9. [PMID: 30504336 DOI: 10.1182/asheducation-2018.1.382] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 11.0] [Reference Citation Analysis]
32 Murakhovskaya I. Rituximab Use in Warm and Cold Autoimmune Hemolytic Anemia. J Clin Med 2020;9:E4034. [PMID: 33322221 DOI: 10.3390/jcm9124034] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
33 Berentsen S. New Insights in the Pathogenesis and Therapy of Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia. Front Immunol 2020;11:590. [PMID: 32318071 DOI: 10.3389/fimmu.2020.00590] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
34 Wong D, Thomas W, Butler A, Sharkey L. Bortezomib for treatment-refractory autoimmune haemolytic anaemia following multivisceral transplantation. BMJ Case Rep 2021;14:e241634. [PMID: 33980556 DOI: 10.1136/bcr-2021-241634] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]